Research Study Search Tool

Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?

Search Results: Prevention, Detection & Risk (13 results)

Here are some research studies that may be enrolling patients like you. Please check with the study contact and your health care provider to confirm your eligibility and see if the study is right for you. Note, our search tool may not be comprehensive and additional research resources can be found here.

Men at High Genetic Risk for Prostate Cancer

Prevention:
Prostate

Men at High Genetic Risk for Prostate Cancer

The National Cancer Institute recently opened a clinical trial for prostate cancer screening in men who are at high risk for prostate cancer due to an inherited mutation. This is trial is for men without prostate cancer, ages 30 to 75, who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, CHEK2, PALB2, RAD51D, BRIP1, FANCA. The trial involves screening MRI of the prostate every two years and biopsy of the prostate if the MRI is abnormal. There is no cost for travel or study-related tests.

GENetic Education Risk Assessment and TEsting Study (GENERATE)

Prevention:
Pancreatic

GENetic Education Risk Assessment and TEsting Study (GENERATE)

The goal of the GENERATE study is to increase the uptake of genetic testing among family members of pancreatic cancer patients who may carry a genetic mutation.

This study involves education about genetic testing, undergoing genetic testing for cancer risk (for those who choose to) and completion of a series of 4 sets of questionnaires.

For more information, visit the study website

Genomic Services Research Program Study for People with Unexpected Genetic Results

Prevention:
Breast
Ovarian
Pancreatic
Prostate

Genomic Services Research Program Study for People with Unexpected Genetic Results

A new study is recruiting people who received unexpected genetic test results about their cancer risk after having genetic testing done for some other reason.

This is a study of people with "secondary results” from genetic testing. Secondary results are unexpected. They are not related to the reason the person had the genetic test but are shared because they may be very important to the person’s health. Most secondary results have to do with high risks for health problems that can be treated or prevented. Many of these results are related to cancer risk. If you think you have received a secondary result, you may be eligible to join this study.

A Pancreatic Cancer Screening Study for High Risk Individuals

Prevention:
Pancreatic

A Pancreatic Cancer Screening Study for High Risk Individuals

The purpose of this study is to screen and detect pancreatic cancer and precancer in people with either a strong family history of pancreatic cancer, or an inherited mutation associated with pancreatic cancer risk.

Magnetic Resonance Imaging (MRI) will be used to screen for early stage pancreatic cancer. Participants will also be asked to donate a blood sample at specific intervals for the creation of a blood bank necessary for the development of a blood-based screening test for pancreatic cancer. 

Pilot Study of Denosumab in BRCA1 or BRCA2 Mutation Carriers Scheduling Risk-Reducing Salpingo-Oophorectomy

Prevention:
Ovarian

Pilot Study of Denosumab in BRCA1 or BRCA2 Mutation Carriers Scheduling Risk-Reducing Salpingo-Oophorectomy

The purpose of this study is to evaluate the effects of denosumab on ovarian cancer risk markers among premenopausal women with a BRCA1 or BRCA2 mutation, who are scheduled to undergo risk-reducing surgery to remove their ovaries and fallopian tubes. Denosumab is an FDA-approved injectable medication that is used to treat osteoporosis and to prevent fractures in cancer patients with bone metastases.

A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups

Prevention:
Pancreatic

A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups

This study will validate and evaluate the performance of the IMMray PanCan-d test for pancreatic cancer diagnosis in comparison to standard of care imaging currently used in pancreatic cancer disease surveillance by the research sites’ institutions.

A Study in Hereditary Breast and Ovarian  Cancer Families to Provide Men With  Up-To-Date Information About the Personal  Importance of Genetic Testing (GEM)

Prevention:
Pancreatic
Prostate

A Study in Hereditary Breast and Ovarian Cancer Families to Provide Men With Up-To-Date Information About the Personal Importance of Genetic Testing (GEM)

The Genetic Education for Men or GEM study, is a clinical trial evaluating educational tools for men from families in which a BRCA1/2 gene mutation has been identified. In order to identify untested men from BRCA1/2 families, we are seeking women who have received positive BRCA1/2 test results and have at least one untested male relative.

Women interested in the study should contact the project coordinator, Mary Kate Ladd, by phone at (877) 687-2720 (toll-free) or by email.

RANKL Inhibition With Denosumab on Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)

Prevention:
Breast

RANKL Inhibition With Denosumab on Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)

The purpose of this study is to evaluate if denosumab can reduce the breast density of premenopausal women who have dense breasts. Denosumab is an FDA-approved injectable medication that is used to treat osteoporosis and to prevent fractures in cancer patients with bone metastases. This study could help us identify novel ways to prevent breast cancer in younger women.

Pancreatic Cancer Early Detection Program

Prevention:
Pancreatic

Pancreatic Cancer Early Detection Program

This is a study looking at esophageal ultrasound and Magnetic Resonance Imaging (MRI) as a screening for pancreatic cancer in high risk individuals. 

The Women Choosing Surgical Prevention (WISP) Trial

Prevention:
Ovarian

Quality of Life:
High Risk But No Cancer

The Women Choosing Surgical Prevention (WISP) Trial

The goal of the WISP Study is to compare whether removal of fallopian tubes only, delaying removal of the ovaries can safely improve sexual functioning and menopausal symptoms compared to standard risk-reducing removal of the ovaries and fallopian tubes (also known as risk-reducing salpingo-oophorectomy or RRSO). You can visit the WISP website for more information.

 

PHACT Study: Population Health and Cancer Testing

Prevention:
Breast
Melanoma
Ovarian
Pancreatic
Prostate

PHACT Study: Population Health and Cancer Testing

The PHACT study offers genetic testing to women and men of Ashkenazi (Eastern European) Jewish ancestry, age 21 or older. This group is at least ten times more likely than the general population to inherit certain kinds of genetic mutations associated with cancer risk. The study is open to people who live in one of the nine Bay Area counties (Alameda, Contra Costa, Marin, Napa, San Francisco, San Mateo, Santa Clara, Solano, Sonoma).  By participating in the UCSF Population Health and Cancer Testing (PHACT) study you will be provided with a saliva collection kit from Color Genomics, a genetic laboratory. Thirty genes will be analyzed, including BRCA1 and BRCA2, to identify mutations that increase the chance of cancer in both men and women of Ashkenazi (Eastern European) Jewish ancestry and genetic counseling support will be available with every test.  For more information, visit the UCSF Center for BRCA Research. 

The WISDOM Study: Women Informed to Screen Depending on Measures of risk

Prevention:
Breast

The WISDOM Study: Women Informed to Screen Depending on Measures of risk

The goal of the Wisdom Study is to determine if breast cancer screening can be made better by personalizing each woman’s mammogram schedule, compared to the current one-size-fits-all, annual approach. The Wisdom Study is designed to end the confusion about when to start and how often to have a mammogram. For more information, visit the WISDOM Study website

Dose-Response of Aerobic Training in Post-Menopausal Women at High-Risk for Development of Breast Cancer

Prevention:
Breast

Dose-Response of Aerobic Training in Post-Menopausal Women at High-Risk for Development of Breast Cancer

In this study, researchers want to determine the optimal amount of exercise needed to change certain factors associated with breast cancer risk for post-menopausal, high-risk women.

Visit the study website for more information.

Additional Results on Clinicaltrials.gov: Prevention, Detection & Risk + CDH1

No Results

Clinical Trial Official Title

FORCE:Facing Our Risk of Cancer Empowered